iifl-logo-icon 1

Bafna Pharmaceuticals Ltd Share Price

83.1
(-1.27%)
Jul 19, 2024|09:43:11 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open84.2
  • Day's High84.2
  • 52 Wk High119
  • Prev. Close84.17
  • Day's Low83.1
  • 52 Wk Low73.25
  • Turnover (lac)0.39
  • P/E27.65
  • Face Value10
  • Book Value34.16
  • EPS3.11
  • Mkt. Cap (Cr.)196.58
  • Div. Yield0
No Records Found

Bafna Pharmaceuticals Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

84.2

Prev. Close

84.17

Turnover(Lac.)

0.39

Day's High

84.2

Day's Low

83.1

52 Week's High

119

52 Week's Low

73.25

Book Value

34.16

Face Value

10

Mkt Cap (₹ Cr.)

196.58

P/E

27.65

EPS

3.11

Divi. Yield

0

Bafna Pharmaceuticals Ltd Corporate Action

14 Aug 2023

12:00 AM

AGM

Announcement Date: 14 Aug, 2023

arrow

22 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

Bafna Pharmaceuticals Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Bafna Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT

19 Jul, 2024|02:52 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 88.29%

Foreign: 0.00%

Indian: 88.29%

Non-Promoter- 11.70%

Institutions: 0.00%

Non-Institutions: 11.70%

Custodian: 0.00%

Share Price

Bafna Pharmaceuticals Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

23.66

23.66

23.66

57.73

Preference Capital

0

0

0

0

Reserves

49.8

38.31

33.11

-6.78

Net Worth

73.46

61.97

56.77

50.95

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

85.14

71.21

42.47

77.2

yoy growth (%)

19.54

67.68

-44.98

18.85

Raw materials

-39.28

-36.52

-19.98

-38.28

As % of sales

46.13

51.28

47.05

49.58

Employee costs

-14.5

-11.98

-10.25

-7.47

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

7.3

5.82

-1.87

-14.27

Depreciation

-5.49

-4.47

-3.26

-3.64

Tax paid

0

0

0

-2.17

Working capital

-0.75

16.58

6.23

-27.03

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

19.54

67.68

-44.98

18.85

Op profit growth

11.6

738.01

-124.32

-3.16

EBIT growth

23.33

-468.5

-76.13

-6.25

Net profit growth

-11.59

-123.11

53.2

-10.93

View Ratios
Particulars (Rupees in Crores.)Mar-2019Mar-2018Mar-2017Mar-2016Mar-2015

Gross Sales

43.36

47.17

64.96

85.32

97.67

Excise Duty

0

0

0

0

0

Net Sales

43.36

47.17

64.96

85.32

97.67

Other Operating Income

0

0

0

0

41.11

Other Income

1.66

31.33

1.14

1.98

4.9

Bafna Pharmaceuticals Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,594.25

125.293,82,370.02867.60.855,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,584.8

77.221,21,645.675310.652,259507.93

Cipla Ltd

CIPLA

1,506.65

32.741,21,616.251,038.40.563,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,185.65

34.71,19,268.911,405.20.253,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,667.5

25.951,11,193.661,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Bafna Pharmaceuticals Ltd

Management

Register Office

Registrar Office

Non-Exec. & Independent Dir.

Babulal Kamlesh Kumar

Chairperson / Executive Director

Shanmugam Hemalatha

Non-Exec & Non-Independent Dir

Akilapriya Chandrashekar Raju

Non-Exec. & Independent Dir.

Palamadai Krishnan Sundaresan

Non-Exec. & Independent Dir.

Ravichandran Chitra

Non Executive Director

Upendar Mekala Reddy

Independent Director

Krishna Yeachuri

Whole-time Director

Vinayak Dinesh Dendukuri

Non Executive Director

Upendar Mekala Reddy

Independent Director

Krishna Yeachuri

Company Sec. & Compli. Officer

A Mohanachandran

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and has been engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a. Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern. During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products. During 2006, Bafna has set up a 100% EOU unit at Madhavaram for the production of tablets and capsule with a capacity of 6973.20 lacs and 2462.40 lacs. This facility has been set up as per revised Schedule M under the Drugs and Cosmetics Act, 1947. The unit has been WHO GMP certified and also ISO 9000 certified. The manufactured products in this factory catered to the markets of Srilanka, Ghana and Ukraine.Bafna was carrying on contract manufacturing for M/s Croslands Pvt. Ltd, a Mumbai based Pharmaceutical Company during the period 1994 to 2000. The companys first product was registered in Srilanka in 1995 and the company made its first export during the same
Read More

Company FAQs

What is the Bafna Pharmaceuticals Ltd share price today?

Down Arrow

The Bafna Pharmaceuticals Ltd shares price on N/A is Rs.₹83.79 today.

What is the Market Cap of Bafna Pharmaceuticals Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bafna Pharmaceuticals Ltd is ₹198.22 Cr. as of 19 Jul ‘24

What is the PE and PB ratio of Bafna Pharmaceuticals Ltd?

Down Arrow

The PE and PB ratios of Bafna Pharmaceuticals Ltd is 27.65 and 2.52 as of 19 Jul ‘24

What is the 52 Week High and Low of Bafna Pharmaceuticals Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Bafna Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Bafna Pharmaceuticals Ltd is ₹73.35 and ₹116.45 as of 19 Jul ‘24

What is the CAGR of Bafna Pharmaceuticals Ltd?

Down Arrow

Bafna Pharmaceuticals Ltd's CAGR for 5 Years at 66.41%, 3 Years at -21.95%, 1 Year at -11.57%, 6 Month at -15.60%, 3 Month at -1.49% and 1 Month at 11.38%.

What is the shareholding pattern of Bafna Pharmaceuticals Ltd?

Down Arrow

The shareholding pattern of Bafna Pharmaceuticals Ltd is as follows:
Promoters - 88.30 %
Institutions - 0.00 %
Public - 11.70 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.